Tjoapack, a contract packaging organization (CPO) serving the pharmaceutical industry, is expanding its contract packaging and cold chain storage services in the United States and the Netherlands. Through these investments, Tjoapack is actively scaling its logistics infrastructure to meet the rising demand for injectable and biologic drug products, strengthen supply chain resilience, and deliver faster turnaround times and enhanced flexibility for its clients.

Expanded Capabilities in the United States

At its Clinton, Tennessee facility, Tjoapack is completing the installation of two advanced packaging lines to enhance high-throughput sterile packaging operations. These include:

• A fully automated, high-speed vial packaging line, capable of processing up to 20 million vials annually, featuring integrated labeling, cartoning, and serialization. The line is slated for commissioning and validation in Q2 2025.
• A semi-automated packaging line for auto-injectors, offering end-to-end traceability and labeling, scheduled for qualification in Q3 2025.

Also, to accommodate growing demand for temperature-sensitive biologics, cold storage capacity at the Clinton facility was expanded and fully validated, with 160 pallet spaces now available under controlled 2–8°C conditions. This GMP-compliant area is already operational and ready to support client supply chains.

Expanded Services in Europe

In Europe, Tjoapack’s Etten-Leur facility has seen a strategic boost in cold chain capacity. Following successful validation, an additional 84 pallet locations will come online in June 2025, bringing the total to 120 pallet spaces at 2–8°C.

The Etten-Leur site has also successfully completed its first commercial project for pre-filled syringe (PFS) packaging. The fully automated PFS line is now in operation and supporting the onboarding of additional client programs. This development aligns with the growing industry shift toward patient-centric drug delivery systems.

Key features of the PFS line include:

• Syringe assembly with or without safety devices
• Automated plunger rod insertion
• Safety device application
• Finger flange and back-stop attachment
• Insertion of ancillary components, such as needles

“These upgrades directly address the accelerating needs of our clients in the biologics and sterile injectable space,” said Dexter Tjoa, CEO of Tjoapack. “By strengthening its injectable packaging and cold chain capabilities, Tjoapack is supporting a wider range of primary container formats, including vials, ampoules, syringes, and auto-injectors, while scaling capacity to better serve both new and existing clients across North America and Europe.”